Education
About Us
Working with TipRanks
Follow Us
Neumora Therapeutics, Inc. (NMRA)
NASDAQ:NMRA
NMRA Stock Chart & Stats
$2.29
-$0.22(-8.53%)
At close: 4:00 PM EST
$2.29
-$0.22(-8.53%)
Day’s Range― - ―
52-Week Range$0.61 - $3.25
Previous CloseN/A
Volume2.95M
Average Volume (3M)490.26K
Market Cap
$304.10M
Enterprise Value-$79.06M
Total Cash (Recent Filing)$171.53M
Total Debt (Recent Filing)$523.00K
Price to Earnings (P/E)―
Beta2.55
Next Earnings
Mar 11, 2026EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.35
Shares Outstanding167,089,110
10 Day Avg. Volume506,087
30 Day Avg. Volume490,256
Financial Highlights & Ratios
PEG Ratio-2.58
Price to Book (P/B)5.89
Price to Sales (P/S)0.00
P/FCF Ratio-9.23
Enterprise Value/Market Cap-0.26
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.81
Enterprise Value/Ebitda0.32
Forecast
1Y Price Target
$9.33Price Target Upside307.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Efficacy In Anxiety‑enriched PopulationNMRA‑511 produced a pronounced efficacy signal on agitation in patients with elevated anxiety at baseline, indicating that enrolling an anxiety‑enriched population could yield clearer, clinically meaningful results in later trials.
Favorable Safety Profile Versus CompetitorsObserved adverse events were mostly mild to moderate with low discontinuation, and absence of a black‑box warning may allow higher dosing and broader use in elderly patients compared with some existing therapies.
Pipeline Breadth And Financial RunwayA diversified pipeline including NMRA‑215 and M4 franchise assets, supported by additional financing and a cash runway into 2027, provides multiple clinical catalysts while reducing near‑term liquidity concerns.
Bears Say
Hyponatremia Safety SignalA serious adverse event of hyponatremia and additional low sodium cases create a material safety question that could necessitate protocol changes, enhanced monitoring, or regulatory review in future studies.
Legacy Clinical Setbacks And Investor SentimentPrevious disappointing results from related programs and KOASTAL‑1 have fostered cautious market sentiment, which may limit share appreciation until convincing pivotal data are delivered.
Small, Underpowered Trial DesignThe Phase 1b signal‑finding study involved few participants and was not powered for definitive efficacy, meaning observed signals may not replicate without rigorous dose‑ranging and larger trials.
Neumora Therapeutics, Inc. News
NMRA FAQ
What was Neumora Therapeutics, Inc.’s price range in the past 12 months?
Neumora Therapeutics, Inc. lowest stock price was $0.61 and its highest was $3.25 in the past 12 months.
What is Neumora Therapeutics, Inc.’s market cap?
Neumora Therapeutics, Inc.’s market cap is $304.10M.
When is Neumora Therapeutics, Inc.’s upcoming earnings report date?
Neumora Therapeutics, Inc.’s upcoming earnings report date is Mar 11, 2026 which is in 61 days.
How were Neumora Therapeutics, Inc.’s earnings last quarter?
Neumora Therapeutics, Inc. released its earnings results on Nov 06, 2025. The company reported -$0.35 earnings per share for the quarter, missing the consensus estimate of -$0.333 by -$0.017.
Is Neumora Therapeutics, Inc. overvalued?
According to Wall Street analysts Neumora Therapeutics, Inc.’s price is currently Undervalued.
Does Neumora Therapeutics, Inc. pay dividends?
Neumora Therapeutics, Inc. does not currently pay dividends.
What is Neumora Therapeutics, Inc.’s EPS estimate?
Neumora Therapeutics, Inc.’s EPS estimate is -0.33.
How many shares outstanding does Neumora Therapeutics, Inc. have?
Neumora Therapeutics, Inc. has 167,089,110 shares outstanding.
What happened to Neumora Therapeutics, Inc.’s price movement after its last earnings report?
Neumora Therapeutics, Inc. reported an EPS of -$0.35 in its last earnings report, missing expectations of -$0.333. Following the earnings report the stock price went down -1.527%.
Which hedge fund is a major shareholder of Neumora Therapeutics, Inc.?
Currently, no hedge funds are holding shares in NMRA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Neumora Therapeutics, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.33 (307.42% Upside)
$9.33 (307.42% Upside)
Hedge Fund Trend
Decreased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $15.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-89.79%
12-Months-Change
Fundamentals
Return on Equity
-104.35%
Trailing 12-Months
Asset Growth
-44.66%
Trailing 12-Months
Company Description
Neumora Therapeutics, Inc.
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
NMRA Stock 12 Month Forecast
Average Price Target
$9.33
▲(307.42% Upside)
Technical Analysis
Abeona Therapeutics
―
AC Immune SA
―
Allogene Therapeutics
―
―
Aardvark Therapeutics, Inc.
―
Ownership Overview
65.90% Insiders
4.04% Mutual Funds
18.69% Other Institutional Investors
8.20% Public Companies and
Individual Investors